宫颈癌预防的未来：从“一刀切”到个性化筛查。
The Future of Cervical Cancer Prevention: From "One-Size-Fits-All" to Personalized Screening.
作者信息
Nygård Mari, Nygård Ståle
机构信息
Department of Research, Cancer Registry of Norway, 0370 Oslo, Norway.
出版信息
J Pers Med. 2023 Jan 17;13(2):161. doi: 10.3390/jpm13020161.
Abstract
Cervical cancer screening represents an excellent model system for the development of personalized cancer-prevention strategies [...].
摘要
宫颈癌筛查是制定个性化癌症预防策略的一个极佳模型系统[...]。
相似文献
1
The Future of Cervical Cancer Prevention: From "One-Size-Fits-All" to Personalized Screening.宫颈癌预防的未来：从“一刀切”到个性化筛查。
J Pers Med. 2023 Jan 17;13(2):161. doi: 10.3390/jpm13020161.
2
Cervical Cancer in the Baltic States: Can Intelligent and Personalized Cancer Screening Change the Situation?波罗的海国家的宫颈癌：智能和个性化癌症筛查能否改变现状？
Acta Med Litu. 2022;29(1):19-26. doi: 10.15388/Amed.2022.29.1.18. Epub 2022 Jun 29.
3
Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers.宫颈癌分子预防策略的现状与未来展望
Indian J Surg Oncol. 2020 Dec;11(4):752-761. doi: 10.1007/s13193-019-00910-z. Epub 2019 Mar 18.
4
Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population.基于完整筛查史的宫颈癌筛查风险分层：将生物信息学应用于一般筛查人群。
Int J Cancer. 2017 Jul 1;141(1):200-209. doi: 10.1002/ijc.30725. Epub 2017 Apr 24.
5
Personalized Medicine and Cervical Screening: Development of Individualized Quantitative Risk Assessments for Cervical Adenocarcinoma and Adenocarcinoma in situ.个体化医学与宫颈癌筛查：宫颈腺癌和原位腺癌个体化定量风险评估的制定。
Acta Cytol. 2021;65(2):158-164. doi: 10.1159/000511620. Epub 2020 Dec 1.
6
Public health genomics and personalized prevention: lessons from the COGS project.公共卫生基因组学与个性化预防：COGS 项目的经验教训。
J Intern Med. 2013 Nov;274(5):451-6. doi: 10.1111/joim.12094.
7
Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.选择最佳组合的宫颈癌预防策略，通过优化程序实现最大效率。
Pharmacoeconomics. 2012 Apr;30(4):337-53. doi: 10.2165/11591560-000000000-00000.
8
Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level.个体化治疗时代的乳腺癌筛查：基于风险和偏好的人群水平策略的概念模型和美国国家癌症研究所倡议。
Cancer. 2014 Oct 1;120(19):2955-64. doi: 10.1002/cncr.28771. Epub 2014 May 15.
9
Matrix factorization for the reconstruction of cervical cancer screening histories and prediction of future screening results.基于矩阵分解的宫颈癌筛查史重建和未来筛查结果预测。
BMC Bioinformatics. 2022 Nov 16;23(Suppl 12):484. doi: 10.1186/s12859-022-04949-8.
引用本文的文献
1
Advancements in Cervical Cancer Screening: Enhancing HPV Testing and Triage Strategies for Improved Risk Assessment.宫颈癌筛查的进展：加强人乳头瘤病毒检测及分流策略以改善风险评估
Biomedicines. 2025 Jul 18;13(7):1768. doi: 10.3390/biomedicines13071768.
2
Navigating the risks: Stakeholder views on risk-based cervical cancer screening.应对风险：利益相关者对基于风险的宫颈癌筛查的看法。
PLoS One. 2025 Mar 5;20(3):e0317986. doi: 10.1371/journal.pone.0317986. eCollection 2025.
3
Women's perspectives on the acceptability of risk-based cervical cancer screening.女性对基于风险的宫颈癌筛查可接受性的看法。
BMC Cancer. 2024 Oct 25;24(1):1314. doi: 10.1186/s12885-024-13050-7.
本文引用的文献
1
Impact of the Mobile Game FightHPV on Cervical Cancer Screening Attendance: Retrospective Cohort Study.手机游戏《抗击HPV》对宫颈癌筛查参与率的影响：回顾性队列研究
JMIR Serious Games. 2022 Dec 13;10(4):e36197. doi: 10.2196/36197.
2
Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study.欧洲癌症检测利用的社会经济不平等：一项横断面研究。
Prev Med Rep. 2022 Feb 8;26:101733. doi: 10.1016/j.pmedr.2022.101733. eCollection 2022 Apr.
3
Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures.人乳头瘤病毒的全基因组下一代测序检测：验证和质量保证程序的重要性。
Viruses. 2021 Jul 8;13(7):1323. doi: 10.3390/v13071323.
4
2020 list of human papillomavirus assays suitable for primary cervical cancer screening.2020 年适合用于宫颈癌初筛的人乳头瘤病毒检测方法列表。
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095. doi: 10.1016/j.cmi.2021.04.031. Epub 2021 May 8.
5
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计：全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
6
Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.欧洲基于 HPV 的宫颈癌初筛：实施现状、挑战与未来计划。
Clin Microbiol Infect. 2020 May;26(5):579-583. doi: 10.1016/j.cmi.2019.09.006. Epub 2019 Sep 17.
7
Perspectives of non-attenders for cervical cancer screening in Norway: a qualitative focus group study.挪威宫颈癌筛查不参与者的观点：一项定性焦点小组研究。
BMJ Open. 2019 Aug 30;9(8):e029505. doi: 10.1136/bmjopen-2019-029505.
8
The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis.阴道微生物群、人乳头瘤病毒与宫颈发育不良：系统评价与网络荟萃分析。
BJOG. 2020 Jan;127(2):171-180. doi: 10.1111/1471-0528.15854. Epub 2019 Jul 17.
9
Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.针对 HPV 疫苗接种女性的宫颈癌筛查策略调整：分层指南的价值。
Eur J Cancer. 2018 Mar;91:68-75. doi: 10.1016/j.ejca.2017.12.018. Epub 2018 Jan 12.
10
A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.一项关于评估即时检测用于人乳头瘤病毒筛查性能的研究的系统评价和荟萃分析。
Sex Transm Infect. 2017 Dec;93(S4):S36-S45. doi: 10.1136/sextrans-2016-053070.
Zotero 插件